Title: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Authors: Regan, Meredith M ×
Leyland-Jones, Brian
Bouzyk, Mark
Pagani, Olivia
Tang, Weining
Kammler, Roswitha
Dell'orto, Patrizia
Biasi, Maria Olivia
Thürlimann, Beat
Lyng, Maria B
Ditzel, Henrik J
Neven, Patrick
Debled, Marc
Maibach, Rudolf
Price, Karen N
Gelber, Richard D
Coates, Alan S
Goldhirsch, Aron
Rae, James M
Viale, Giuseppe
Breast International Group (BIG) 1-98 Collaborative Group #
Issue Date: Mar-2012
Publisher: Oxford University Press
Series Title: Journal of the National Cancer Institute vol:104 issue:6 pages:441-451
Abstract: Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of CYP2D6 polymorphisms.
ISSN: 0027-8874
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science